Skip to main content

Weather alert

Due to Hurricane Isaias, our Patient Service Centers in affected areas may be closed. We ask that patients please double check your appointment status to ensure your designated Patient Service Center is operational. For site-specific information, please use Find a location and enter your zip code.

Hide
Quest Diagnostics

Presence of Novel Psychoactive Substances in Confirmed Negative Benzodiazepine Clinical Urine Specimens

SOFT-THIAFT 2026

Joint meeting between Society of Forensic Toxicologists and The International Association of Forensic Toxicologists

Chicago, IL, Sep 19-24, 2026

Poster presentation: Presence of Novel Psychoactive Substances in Confirmed Negative Benzodiazepine Clinical Urine Specimens

(abstract can be found on page 560 in abstract book: link above)

Authors: Yeomans NR, Neifeld JR, Pacana AL, Bland AA, Meli TM, Bartock SH

Medical Specialty: Prescription drug monitoring, Toxicology

Related content

On-Demand Webinar
The Growing Crisis of Novel Psychoactive Substances
Audio Podcast
Novel Psychoactive Substances (NPS): A Dangerous, Widespread Public Health Issue
Test FAQ
Novel Psychoactive Substances (NPS) Panel

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.